<DOC>
	<DOCNO>NCT01187901</DOCNO>
	<brief_summary>The purpose study determine randomize , placebo-controlled , phase II trial combination sulindac erlotinib cause significant regression duodenal colorectal adenoma familial adenomatous polyposis ( FAP ) attenuate FAP ( AFAP ) patient .</brief_summary>
	<brief_title>A Clinical Trial COX EGFR Inhibition Familial Polyposis Patients</brief_title>
	<detailed_description>This single-center , phase-II , six-month-long , placebo-controlled , double blind , randomize trial epidermal growth factor receptor ( EGFR ) inhibitor , erlotinib ( Tarceva ) cyclooxygenase ( COX-2 ) inhibitor , sulindac patient familial adenomatous polyposis ( FAP ) attenuate FAP . FAP autosomal dominant inherit colon cancer predisposition 100 % risk colon cancer absence preventive care ( endoscopy surgery ) . Efficacious chemoprevention duodenal adenoma unmet clinical need FAP patient would reduce morbidity duodenectomy risk duodenal adenocarcinoma . Currently Food Drug Administration ( FDA ) -approved chemopreventive agent celecoxib result modest reduction duodenal colorectal polyp associate cardiac toxicity effective dos . If show combinatorial inhibition COX-2 EGFR activity lead successful regression duodenal adenomatous polyp FAP , could use effective chemopreventive regimen FAP patient duodenal adenoma undergone surgical resection duodenal adenomas many rectal adenoma . FAP AFAP patient screen endoscopy presence 5 duodenal polyp , randomize either A ) erlotinib 75 mg/day sulindac 150 mg/day B ) placebo 6 month . The endpoint endoscopy 6 month . Primary Aim : To determine combination sulindac erlotinib cause significant regression duodenal polyp burden 6 mohths FAP attenuate FAP patient . Secondary Aim : To measure combination sulindac erlotinib cause reduction total duodenal polyp count , change duodenal polyp burden count stratify genotype initial polyp burden .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>Patients 18 year old clinical genetic diagnosis FAP attenuate FAP . Presence duodenal polyp sum diameter ≥ 5mm . Minimum two week since major surgery WHO performance status ≤1 Adequate bone marrow function show : normal leukocyte count , platelet count ≥ 120 x 109/L , Hgb &gt; 12 g/dL Adequate liver function show : normal serum bilirubin ( ≤ 1.5 Upper Limit Normal { ULN } ) serum transaminase ( ≤ 2.0 ULN ) Patient must discontinue take Nonsteroidal antiinflammatory drug ( NSAIDS ) within one month treatment initiation . Patients must able provide write informed consent . Prior treatment investigational drug within precede 4 week . Malignancies within past 3 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin . Patients severe and/or uncontrolled medical condition condition could affect participation study determine Principal Investigator : 1 . Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month prior first study treatment , serious uncontrolled cardiac arrhythmia 2 . Severely impaired lung function 3 . Any active ( acute chronic ) uncontrolled infection/ disorder . 4 . Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy 5 . Liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis Screening clinical laboratory value indicate follow : 1. anemia 2. thrombocytopenia 3. leucopenia 4. elevation transaminase great 2X ULN 5. elevation bilirubin &gt; 1.5 X ULN 6. alkaline phosphatase elevation &gt; 1.5 X ULN 7. increase creatinine , urinary protein , urinary cast outside clinically normal range . Gastrointestinal bleeding ( symptoms include dyspnea , fatigue , angina , weakness , malaise , melena , hematochezia , hematemesis , anemia abdominal pain require clinical assessment rule gastrointestinal bleeding ) . Patient currently take anticoagulation medication . Women pregnant breast feeding . Patients know hypersensitivity sulindac erlotinib excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Familial Adenomatous Polyposis</keyword>
	<keyword>Attenuated Familial Polyposis</keyword>
</DOC>